GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Cash, Cash Equivalents, Marketable Securities

Emmaus Life Sciences (Emmaus Life Sciences) Cash, Cash Equivalents, Marketable Securities : $1.51 Mil (As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Cash, Cash Equivalents, Marketable Securities?

Emmaus Life Sciences's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 ($1.77 Mil) to Jun. 2023 ($1.36 Mil) but then increased from Jun. 2023 ($1.36 Mil) to Sep. 2023 ($1.51 Mil).

Emmaus Life Sciences's annual cash, cash equivalents, marketable securities declined from Dec. 2020 ($2.49 Mil) to Dec. 2021 ($2.28 Mil) and declined from Dec. 2021 ($2.28 Mil) to Dec. 2022 ($2.02 Mil).


Emmaus Life Sciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Emmaus Life Sciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Cash, Cash Equivalents, Marketable Securities Chart

Emmaus Life Sciences Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 29.70 2.49 2.28 2.02

Emmaus Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 2.02 1.77 1.36 1.51

Emmaus Life Sciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Emmaus Life Sciences  (OTCPK:EMMA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Emmaus Life Sciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Executives
Seah H. Lim director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee director, officer: Vice Chairman & COO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara director, 10 percent owner, officer: Chairman and CEO 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi director 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark officer: SVP, Clinical Development 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich officer: CIO & SVP 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood director 956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii officer: Chief Financial Officer 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato director 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran officer: Chief Administrative Officer 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey director 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki officer: Sr. VP Finance 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501